Drug Profile

MIRA 55

Alternative Names: MIRA-55

Latest Information Update: 04 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MIRA Pharmaceuticals
Class Analgesics; Anti-inflammatories; Anxiolytics; Cannabinoids; Nootropics; Small molecules
Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Inflammatory pain
Discontinued Anxiety disorders; Cognition disorders

Most Recent Events

01 Sep 2026 MIRA Pharmaceuticals plans a IND submission with US FDA in inflammatory pain in first quarter of 2027
30 Jul 2026 Discontinued - Preclinical for Anxiety disorders in USA (PO)
30 Jul 2026 Discontinued - Preclinical for Cognition disorders in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com